Effects of valproate sodium on pituitary gonadotropin in adolescent girls with epilepsy.
- Author:
Yan-Hua CAI
1
;
Hua WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Anticonvulsants; therapeutic use; Child; Epilepsy; blood; drug therapy; Female; Gonadotropins, Pituitary; blood; Humans; Valproic Acid; therapeutic use
- From: Chinese Journal of Contemporary Pediatrics 2011;13(9):725-727
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of valproate sodium (VPA) on the level and axle of pituitary gonadotropin in adolescent girls with epilepsy.
METHODSTwenty-three adolescent girls with epilepsy aged from 8 to 14 years were treated with VPA for 1 year. The levels of serum pituitary gonadotropin including estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin and testosterone were measured before treatment and 3 months, 6 months and 1 year after treatment.
RESULTSThe serum levels of estradiol, follicle-stimulating hormone, luteinizing hormone and prolactin in the children with epilepsy were not significantly different during the 1 year VPA treatment compared with pretreatment. However, the serum level of testosterone was reduced 1 year after treatment (0.4±0.3 ng/mL) compared with pretreatment (0.7±0.4 ng/mL) and 3 months after treatment (0.7±0.4 ng/mL) (P<0.05).
CONCLUSIONSVPA treatment for 1 year does not increase serum levels of androgen in adolescent girls with epilepsy, suggesting that VPA is an ideal choice of treatment for the girls.
